newsfilter
← Latest News
Business Wire·

Anacor Pharmaceuticals to Host Conference Call Tomorrow, July 13, 2015 at 7:30 A.M. ET to Discuss Top-Line Results From Crisaborole Phase 3 Pivotal Studies in Patients With Mild-to-Moderate Atopic Dermatitis

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will host a conference call at 7:30 a.m. ET tomorrow, Monday, July 13, 2015 to discuss the top-line results from its Phase 3 pivotal studies of Crisaborole Topical Ointment, 2% (formerly AN2728) for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. A press release announcing the top-line results will be issued tomorrow prior to the call.